LYS006X
Total Payments
$508,497
Transactions
31
Doctors
4
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $82,420 | 16 | 3 |
| 2019 | $265,434 | 9 | 1 |
| 2018 | $160,642 | 6 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $508,497 | 31 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF LYS006 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE | Novartis Pharmaceuticals Corporation | $405,276 | 0 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF LYS006 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE | NOVARTIS PHARMACEUTICALS CORPORATION | $93,141 | 0 |
| A RANDOMIZED, MULTI-CENTER,, SUBJECT AND INVESTIGATOR BLINDED, PLACEBO CONTROLLED, PARALLEL GROUP PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF LYS006 IN PATIENTS WITH MILD TO MODERATE ULCERATIVE COLITIS | Novartis Pharmaceuticals Corporation | $10,080 | 4 |
Top Doctors Receiving Payments for LYS006X
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $415,356
- NOVARTIS PHARMACEUTICALS CORPORATION $93,141
Product Information
- Type Drug
- Total Payments $508,497
- Total Doctors 4
- Transactions 31
About LYS006X
LYS006X is a drug associated with $508,497 in payments to 4 healthcare providers, recorded across 31 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $82,420 was paid across 16 transactions to 3 doctors.
The most common payment nature for LYS006X is "Unspecified" ($508,497, 100.0% of total).
LYS006X is associated with 3 research studies, including "A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTI CENTER STUDY IN PARALLEL GROUPS TO ASSESS THE EFFICACY AND SAFETY OF LYS006 IN PATIENTS WITH MODERATE TO SEVERE INFLAMMATORY ACNE" ($405,276).